pharmaceutical investing Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018
medical device investing AIT Therapeutics Receives Patent Allowance for Delivery of Inhaled Nitric Oxide at Concentrations of at Least 160ppm for Treatment of Bronchiolitis in Infants
pharmaceutical investing Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554
Alvopetro Announces Year End 2025 Financial Results, Q1 2026 Dividend of US$0.12/share, and Filing of our AIF
QIMC Reports Results from Hole 1 DDH-26-01 at West-Advocate Natural Hydrogen Project, Nova Scotia; R2G2(TM) Exploration Model Applied
